Anbio Biotechnology (NNNN)
Anbio Biotechnology will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$5.00 - $6.00
Shares Offered
1,600,000
Deal Size
$8.80M
Anbio Biotechnology Revenue
Anbio Biotechnology had revenue of $9.50M in the twelve months ending June 30, 2024. In the year 2023, Anbio Biotechnology had annual revenue of $6.71M, down -71.49%.
Revenue (ttm)
$9.50M
Revenue Growth
-71.49%
P/S Ratio
25.41
Revenue / Employee
$351,928
Employees
27
Market Cap
241.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 6.71M | -16.83M | -71.49% |
| Dec 31, 2022 | 23.54M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNNNN News
- 4 days ago - U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings - Seeking Alpha
- 5 days ago - Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch - Seeking Alpha
- 7 days ago - Anbio Biotechnology IPO Registration Document (F-1) - SEC